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Abstract
Background—Concurrent chemotherapy plus radiation therapy (chemoRT) is the standard 
treatment for stage IIIA(N2) non-small cell lung cancer (NSCLC), a common disease entity. Phase 
II studies demonstrated feasibility of resection after chemoRT with encouraging survival rates. 
This phase III trial compared both approaches.
Methods—Patients with stage T1-3pN2M0 NSCLC were randomized before induction chemoRT 
(2 cycles of cisplatin and etoposide [PE] concurrent with 45 Gy RT). If no progression, arm 1 
underwent resection, and arm 2 continued RT uninterrupted to 61 Gy. Two additional cycles of PE 
were given. The primary endpoint was overall survival (OS).
Findings—Progression-free survival for 396 eligible patients was superior in arm 1: median 12.8 
versus 10.5 months, p=0.017, hazard ratio (HR) 0.77 (0.62,0.96); 5-yr 22.4% versus 11.1%. 
Median OS was 23.6 versus 22.2 months, p=0.24, HR 0.87 (0.70,1.10). Five-year survivals were 
arm 1, 27.2% and arm 2, 20.3%; odds ratio 0.63 (0.36,1.10, p=0.10). N0 status at thoracotomy 
predicted median OS of 33.5 months (5-year, 41.8%). Major chemoRT toxicities were neutropenia 
and esophagitis. Treatment-related death occurred in 16 (7.9%) patients on arm 1, of which 14 
were post-pneumonectomy; and in 4 (2.1%) on arm 2. An exploratory analysis showed improved 
OS for patients who underwent lobectomy versus a matched cohort on chemoRT alone, but not for 
those undergoing pneumonectomy (matched similarly).
Interpretation—There was no significant survival advantage to surgery after chemoRT, despite 
improved PFS. Both chemoRT with definitive RT and chemoRT followed by resection (preferably 
lobectomy) are options for patients with stage IIIA(N2) NSCLC.
Historically, patients with stage IIIA non-small-cell lung carcinoma (NSCLC) with 
clinically-evident, ipsilateral mediastinal nodal metastases (N2) had poor outcomes 
following single modality treatment with either surgical resection or radiotherapy (RT). 
(1-4) Addition of chemotherapy to RT (chemoRT) significantly improved survival for this 
stage subset and is now considered standard care. (5-8) Subsequent phase III trials 
demonstrated superior survival with concurrent chemoRT compared with sequential 
administration. (9-11)
Phase II pilot studies were conducted that tested the role of surgical resection after induction 
therapy with either chemotherapy or chemoRT in order to optimize local control after 
systemic treatment. The results were provocative with long-term survival rates higher than 
anticipated. (11-13) However, these studies demonstrated significant toxicity, postoperative 
morbidity and mortality, and were criticized because patients enrolled on these trials had 
heterogeneous substages of disease and seemed unusually fit as compared to the general 
stage III population.
We designed a phase III trial (R9309, INT0139) in patients with uniform, pathologically-
documented stage IIIA(pN2) NSCLC (confirmed ipsilateral mediastinal nodal metastases), 
based on two previous phase II studies conducted by the Southwest Oncology Group 
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(SWOG). (14, 15) A standard concurrent chemoRT induction with the RT dose to 45 Gy, 
followed by surgical resection, was compared to continuing to 61 Gy without surgery. The 
objectives were to 1) assess whether resection resulted in a significant improvement in 
survival outcomes compared to chemoRT alone, 2) evaluate the toxicity in each arm, and 3) 
report patterns of local and distant disease recurrence.
METHODS
All patients provided informed consent after local institutional review board approval. This 
trial was funded by the National Cancer Institute with high priority designation, and 
administered by the Radiation Therapy Oncology Group (RTOG, R9309), with participation 
by SWOG, National Cancer Institute of Canada Clinical Trials Group, Eastern Cooperative 
Oncology Group, Cancer and Leukemia Group B and North Central Cancer Treatment 
Group. RTOG was responsible for data collection, analysis and publication.
Eligibility Criteria
Staging included a computed tomographic (CT) scan of the chest, liver and adrenal glands; 
bone scan; and CT or MRI of the brain. The International Staging System for lung cancer 
was employed. (1) All patients had stage IIIA(pN2) disease: T1, T2 or T3 primary NSCLC 
was required with pathologic proof of N2 involvement (via biopsy of ipsilateral mediastinal 
nodes visible on radiographs by any of a number of protocol-specified standard procedures). 
If contralateral mediastinal nodes larger than 1 cm were visible on the CT scan, biopsy was 
required to exclude N3 (stage IIIB) disease.
Patients were evaluated by a thoracic surgeon, radiation oncologist and medical oncologist 
(each approved to participate through a centralized questionnaire process) to establish that 1) 
N2 disease was present to the extent that chemoRT was considered the standard approach, 
not upfront resection; and 2) the disease was potentially technically resectable. Pulmonary 
function criteria were mandated (predicted post-resection FEV1 of at least 800 cc on 
quantitative perfusion scan if FEV1 overall was less than 2000 cc; standard formula 
specified in protocol). As needed, pulmonary medicine specialists were also consulted to 
confirm pulmonary fitness for a potential resection. The Karnofsky performance status 
(KPS) was either 90 or 100; or, if 70 or 80, the albumin of was least .85X normal with <10% 
weight loss within the previous 3 months.
Study Design
Eligible patients were stratified by primary T designation (T1 vs T2 vs T3), KPS (90 or 100 
vs 70 or 80) and contralateral mediastinal nodal sampling (yes vs no). Randomization was 
either to arm 1, induction chemoRT followed by surgery; or arm 2, the same induction 
chemoRT with completion of definitive-dose RT. The induction chemoRT was cisplatin (50 
mg/m2 days 1, 8, 29, 36), and etoposide (50 mg/m2 days 1-5 and 29-33), plus 45 Gy thoracic 
RT beginning day 1, in 1.8 Gy daily fractions. Disease re-evaluation by CT scan plus repeat 
pulmonary function tests was done 2-4 weeks after completion of RT in arm 1, and 7 days 
before completion of induction chemoRT in arm 2. If there was no disease progression and 
the patient remained medically fit, a complete surgical resection (with protocol-specified 
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mediastinal lymph node sampling/dissection) was performed 3-5 weeks after completion of 
RT in arm 1, or the RT was continued to 61 Gy without interruption in arm 2. Patients 
received 2 cycles of consolidation chemotherapy (same doses and schedule as during 
induction). Dose reduction guidelines were specified for chemoRT, with central quality 
control.
A chest CT scan was scheduled 4-6 weeks after completion of the last chemotherapy cycle. 
Patients were followed every 2 months for 1 year, every 3 months for 2 years, then every 6 
months indefinitely. CT scans of the thorax and upper abdomen and MRI or CT of the brain 
were done at 12, 18, and 24 months and annually thereafter.
Statistical Considerations
Un-blinded treatment arm assignment used Zelen's randomized permuted block within 
strata. (16) Intent-to-treat analyses used only eligible patients per RTOG policy. The 
primary endpoint was overall survival (OS), defined as time from randomization to death by 
any cause. Secondary endpoints were progression-free survival (PFS), defined as time from 
randomization to disease progression, secondary primary, or death by any cause; toxicity; 
and patterns of failure.
The sample size was calculated using a non-stationary Markov process to model survival 
using the Lakatos method (17), assuming a one-sided log-rank test with a Type I error rate 
of 0.05 and 93% statistical power, and minimum follow-up of 2.5 years. Only two-sided p-
values are reported. Two interim analyses were specified after 33% and 67% of patients 
were followed for at least 2.5 years.
The target sample size was 612 patients (556 eligible) to observe 507 deaths to detect 10% 
absolute improvement in the surgical arm, assuming 25% 2-year OS with chemoRT. This 
was recalculated upon recommendation of the Data Safety and Monitoring Committee 
(DSMC), based on slower accrual than projected and updated survival rates from the two 
phase II trials that represented each arm. (14, 15) The revised sample size was 510 patients 
(484 eligible).
OS and PFS were analyzed by log-rank test and multivariate analyses used the Cox 
proportional hazards model. (18) The adjusted alpha at final analysis was 0.0487. Only the 
unadjusted estimates and confidence intervals are reported here, as the largest difference 
(between unadjusted and adjusted) was 0.002 for HRs and 0.04 for OS and PFS rates. All 
figures display Kaplan-Meier estimates. (19) Stepwise selection was used in Cox modeling, 
including sex, weight loss (<5 kg or ≥5 kg), number of positive nodal stations (1 or 2-3), T-
stage (T1 vs T2 vs T3), histology (non-squamous vs squamous), age (≤ 60 vs > 60 years 
old), KPS (90 or 100 vs 70 or 80), and LDH (normal vs abnormal). Exploratory logistic 
regression for factors associated with 5-year survival was conducted.
An unplanned, exploratory OS analysis was added for hypothesis-generation, prompted by 
unexpectedly high postoperative mortality rates. Patients in arm 1 who underwent 
pneumonectomy were matched one-to-one to arm 2 patients based on age (+/− 5 years), sex, 
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KPS (70 or 80 and 90 or 100), and clinical T-stage (exact match). Patients in arm 1 who had 
a lobectomy were matched one-to-one on the same characteristics to patients on arm 2.
RESULTS
Study Conduct and Reporting
Accrual occurred from March, 1994 through November, 2001. Due to the extended accrual 
period resulting in sufficient events, the DSMC (privy to the survival curves by arm) 
recommended closure at 429 randomized patients. A PFS analysis and initial OS were 
previously presented, with a subsequent update. (20, 21) Definitive estimates are now 
available for all endpoints, with median follow-up for all patients of 22.5 months (range: 
0.9-125.1 months) and 69.3 months (range: 6.2-125.1 months) for patients still alive.
Study Population and Treatment Delivered
Of 429 patients randomized (Figure 1), 396 patients (92%) were eligible (202, arm 1 and 
194, arm 2). The primary reasons for ineligibility were wrong stage or incomplete staging on 
central review. The ineligibility rate and reasons did not differ significantly by arm. Patient 
and tumor characteristics were well balanced across the treatment groups (Table 1).
Upon completion of induction chemoRT and re-evaluation, 177 patients (87.6%) in arm 1 
were eligible for surgery, and 164 (81.2%) underwent thoracotomy (Figure 1). A complete 
resection was accomplished in 144 patients (71.3%), incomplete resection in 11 (5.4%) and 
no resection in 9 (4.5%). Of the 155 resections, there were 3 wedge resections, 98 
lobectomies and 54 pneumonectomies (29, right; 25, left). Consolidation chemotherapy was 
started as specified in 121 (59.9%) patients. At the reevaluation point during the last week of 
induction chemoRT in arm 2, 179 (92.3%) patients were eligible to continue consolidation 
chemoRT without a break, and 155 (79.9%) began consolidation chemotherapy per protocol 
guidelines (Figure 1).
There was no significant difference between arms in the amount of chemotherapy delivered 
per protocol during induction chemoRT (arm 1, 95.0%; arm 2, 91.7%). Consolidation 
chemotherapy was completed in 111 (55.0%) on arm 1 and 144 (74.6%) on arm 2, p<0.0001 
(Figure 1). RT was delivered per protocol or with acceptable variation in 193 (95.5%), arm 
1; and 154 (79.4%), arm 2, p<0.0001.
Morbidity and Treatment-Related Mortality
Toxicities are summarized in Table 2. The most common grade 3 or 4 toxicity was 
neutropenia, which occurred in 77 (38.1%) patients on arm 1 and 80 (41.2%) on arm 2. 
Infections were infrequent. Grade 3/4 esophagitis was reported in 20 (9.9%) patients on arm 
1 and 44 (22.7%) on arm 2 (p=0.0006). Pneumonitis or other grade 3/4 respiratory 
complications occurred in 18 (8.9%) patients on arm 1 and 28 (14.4%) on arm 2 (p=NS). 
Grade 3/4 nausea and/or emesis was reported in 29 (14.4%) patients on arm 1 and 26 
(13.4%) on arm 2 (p=NS). There was no difference between arms in grade ≥3 toxicity 
during induction chemoRT, whereas hematologic toxicity was greater in arm 2 during 
consolidation chemotherapy (56% versus 36%).
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There were no treatment-related deaths during induction chemoRT on either arm. 
Subsequently, 16 (7.9%) patients died of causes not due to cancer on arm 1, 10 of which 
occurred within 30 days of thoracotomy. Of these 16 deaths, 14 were after pneumonectomy, 
1 followed lobectomy, and 1 occurred in a patient who did not undergo thoracotomy. Causes 
were ARDS, 9; other respiratory, 4; cardiac, 2; hemorrhage, 1. There were 4 (2.1%) patients 
on arm 2 who died of treatment-related causes (3, non-ARDS respiratory; 1, other) during or 
after consolidation chemoRT.
Progression-Free Survival and Overall Survival
PFS was significantly prolonged in arm 1 vs arm 2 (Figure 2A): median 12.8 vs 10.5 
months, logrank p=0.017, hazard ratio 0.77 (95% CI 0.62,0.96). The 5-year PFS (+/− 95% 
CI) was 22.4% (6) on arm 1 vs 11.1% (5) on arm 2. OS (Figure 2B) was not significantly 
improved in arm 1 vs arm 2: median 23.6 vs 22.2 months, logrank p=0.24, hazard ratio 0.87 
(95% CI 0.70, 1.10). There were more patients on arm 1 alive without progression (21.3% 
vs 11.3%, p=0.008), but more died without progression on arm 1 (17.8% vs 9.8%, p=0.02). 
By year 5, there was a 7% absolute difference favoring the surgical arm, with 27.2% (6) 
alive vs 20.3% (6) and an odds ratio of 0.63 (0.36,1.10). No other factor predicted 5-year 
survival by logistic regression.
The Cox OS model found several independent predictors of outcome, including absence of 
major weight loss (p=0.003), female sex (0.009), and one N2 nodal station positive at 
diagnosis vs more (p=0.024). Treatment arm, age, KPS, T stage, LDH, and histology were 
not retained in the model. Because different factors determined whether a pneumonectomy 
or lobectomy was chosen, a survival comparison of the pneumonectomy vs lobectomy 
cohorts was not conducted.
Pathology Findings and Patterns of Disease Recurrence
The post-induction pathology findings in arm 1 by T and N category were tabulated 
according to percent of the 164 thoracotomies performed as well as percent of the total 
patient enrollment of 202, respectively, for each category. These were T0N0, 29 (17.7, 
14.4); T1N0, 31 (18.9%, 15.3%), T2-4N0, 16 (9.8%, 7.9%); N1-3, 85 (51.8%, 42.1%); 
unknown, 3 (1.8%, 1.5%). Of the 29 T0N0 specimens, a pneumonectomy had been 
performed in 13 (44%). Figure 3 depicts OS by grouping pathologic stage according to N 
status. Median and 5-year survivals were T(any)N0, 34.4 months and 41.0%; T(any)N1-3 or 
unknown, 26.4 months and 23.8%; and no surgical resection, 7.9 months and 8.3% 
(p<0.0001). The T0N0 subset had a median survival of 39.8 months and 5-year survival of 
41.9%. Post-induction pathologic categories are unknown in arm 2, thus comparisons 
between arms are not feasible within TN subsets.
There were no differences in sites of first progression except there were fewer local-only 
relapses in arm 1 (10.3%) than arm 2 (22.2%). These occurred at the primary tumor site only 
(2.5% vs 14.4%); hilar, mediastinal or supraclavicular nodes only (6.9% vs 3.1%), and both 
(1.0% vs 4.6%). The brain was the sole initial site of relapse in 11.4% vs 14.9%. Other 
distant sites of recurrence occurred in 37.1% vs 41.8%, respectively.
Albain et al. Page 6













Unplanned, Exploratory Matching Analysis
The OS matching analysis on four prestudy factors for arm 1 against arm 2 subsets was 
feasible for 90 of the 98 lobectomies and 51 of the 54 pneumonectomies. OS was 
significantly improved on the surgical arm if a lobectomy was performed compared to the 
OS of the matched cohort in the chemoRT arm (Figure 4A). Median survivals were 33.6 vs 
21.7 months, logrank p=0.002, with 5-year survivals of 36.1% vs 17.8%. There was a 
nonsignificant trend toward worse OS in arm 1 for the pneumonectomy group vs the OS for 
the matched cohort in arm 2 (Figure 4B). Median survivals were 18.9 vs 29.4 months, 3-year 
36.3% vs 45.0%, and 5-year 21.9% vs 23.6%.
DISCUSSION
This goal of this landmark phase III study was to evaluate the potential benefit of surgical 
resection after chemoRT for a common disease entity, stage IIIA(N2) NSCLC. These 
patients were judged fit for a rigorous treatment regimen and had disease for which 
chemoRT alone was deemed standard therapy, yet was technically resectable. This 
population stands in marked contrast to another group of patients with less extensive N2 
disease who were included in the randomized trials of induction chemotherapy followed by 
surgery against a surgical-only control arm. (12, 13, 22-24) The results of our study 
demonstrating no statistical improvement in the primary OS endpoint, despite significantly 
prolonged PFS, for patients who underwent trimodality therapy with chemoRT followed by 
surgical resection have broad clinical implications.
Both treatment regimens employed in this trial resulted in median and 5-year survivals better 
than expected from phase II data in stage IIIA(N2) NSCLC. (11,12) Although OS was not 
improved by the addition of surgery, there was a trend for increased 5-year survival after 
trimodality therapy. Potential reasons for lack of OS benefit despite significant prolongation 
in PFS include inadequate power and less delivery of cycles 3 and 4 of chemotherapy in the 
surgical arm. However, it is unclear whether this additional chemotherapy has any value, 
based on randomized data in the non-surgical setting.
The lack of OS benefit by surgery in our trial may relate in large part to the high 
postoperative death rate following pneumonectomy, predominantly due to ARDS and other 
respiratory causes. This observation led to the exploratory matching analysis, which 
generated the hypothesis that trimodality therapy may be beneficial if a complete resection 
by lobectomy can be performed after chemoRT or if mortality from pneumonectomy can be 
avoided. There are obvious limitations to this type of analysis, so it should not be used as the 
sole basis to select therapy. The necessity for pneumonectomy in many patients was 
probably related to other adverse prognostic factors. However, it is revealing that 44% of the 
pT0N0 specimens were resected via pneumonectomy. Thus, this exploratory analysis could 
be useful as an adjunct in decision-making, to raise a caution flag when considering a 
trimodality prescription with pneumonectomy.
Our trial is unique in posing the question of surgical resection in stage IIIA(N2) NSCLC 
after induction chemoRT compared to the present standard of concurrent chemoRT in a 
population in which up-front surgery cannot be recommended. Although the EORTC 
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conducted a phase III trial in stage IIIA(N2) NSCLC that randomized patients to surgery or 
RT after response to induction chemotherapy (25), the study differed from ours in several 
important ways. The EORTC control arm of chemotherapy followed by RT is no longer 
considered standard (9-11), and the fate of the entire denominator of patients is not known 
(only the responding patients were randomized), in contrast to the upfront randomization in 
our trial. Similar to our experience, accrual was protracted because of the difficult 
randomization and no OS benefit was observed. The median and 5-year survivals in both 
arms of the EORTC study were inferior to the present study, although this could be 
explained in part by different entry criteria between the two trials.
The North America Intergroup study provides the first broad application of both the 
concurrent chemoRT control and trimodality approaches deemed promising in phase II 
studies (12-15), to allow comparison of treatment delivery and toxicity profiles between 
arms. The induction chemoRT was well tolerated in both arms, with excellent treatment 
compliance. Treatment-related mortality due to respiratory causes was worse in the surgical 
arm and fewer patients could complete consolidation chemotherapy after surgery. However, 
patients enrolled on the chemoRT arm had a greater rate of severe esophagitis and other 
toxicities during consolidation chemoRT and were less likely to complete the prescribed RT.
Given the prolonged accrual period needed to complete trials that address whether there is 
benefit to inclusion of surgery versus a non-surgical approach, it is highly unlikely that a 
prospective trial will be done to validate the hypothesis raised by our exploratory analysis 
(that trimodality approaches are superior if lobectomies can be performed). Thus, medically 
fit patients with stage IIIA(N2) NSCLC deserve evaluation by a team with expertise in 
multimodality therapy, during which treatment options can be considered. Based on this 
study, patients should be counseled regarding risks versus potential benefits of both 
definitive chemoRT alone as well as a surgical resection (preferably by lobectomy) after 
chemoRT.
ACKNOWLEDGEMENTS
The authors thank the additional North American Intergroup discipline chairs and others who provided advice or 
assistance during the design or conduct of this study: Roger Byhardt, MD, Yvon Courmier, MD, Claude 
Deschamps, MD, Bahman Emami, MD, David Ettinger, MD, Mark Krasna, MD, Randolph Marks, MD, Thomas 
Rice, MD, Stephen Seagren, MD, and Henry Wagner, MD. Also, we thank the membership of the Lung Cancer 
Committees of the Southwest Oncology Group, National Cancer Institute of Canada Clinical Trials Group, Eastern 
Cooperative Oncology Group, Cancer and Leukemia Group B, and the North Central Cancer Treatment Group for 
their support of this study over the long accrual period. We especially acknowledge the lung cancer survivors who 
were treated and followed on this protocol and the lay advocates who supported this trial design.
This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by 
the National Cancer Institute, DHHS: CA21661, CA37422, CA32115, CA46441, CA77202, CA49957, CA03927, 
CA25224; Canadian Cancer Society NCIC10362.
REFERENCES
1. Mountain CF. Prognostic implications of the International Staging System for lung cancer. Semin 
Oncol. 1988; 3:236–245. [PubMed: 3381104] 
2. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Amer. 1987; 
67:1037–49. [PubMed: 3629423] 
Albain et al. Page 8













3. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients 
with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by 
the Radiation Therapy Oncology Group. Cancer. 1987; 59:1874–1881. [PubMed: 3032394] 
4. Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in 
patients with locally advanced, unresectable non-small cell lung cancer. Annals Int Med. 1990; 
113:33–38.
5. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus 
high-dose radiation versus radiation alone in stage III non-small-cell-lung cancer. N Engl J Med. 
1990; 323:940–5. [PubMed: 2169587] 
6. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern 
Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally 
advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995; 87:198–205. [PubMed: 
7707407] 
7. LeChevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and 
radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial in 353 
patients. J Natl Cancer Inst. 1991:417–423. 1991. [PubMed: 1847977] 
8. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in 
the treatment of locally advanced, unresectable, non-small-cell lung cancer – a meta-analysis. Ann 
Intern Med. 1996; 125:723. [PubMed: 8929005] 
9. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic 
radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-
small-cell lung cancer. J Clin Oncol. 1999; 17:2692–2699. [PubMed: 10561343] 
10. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of 
sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell 
lung cancer: RTOG 9410. Proc Amer Soc Clin Oncol. 2003; 22:621.
11. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J 
Clin Oncol. 2005; 23:3257–69. [PubMed: 15886313] 
12. Eberhardt WE, Albain KS, Pass H, Putnam JB, Gregor A, Assamura H, Mornex F, Senan S, 
Belderbos J, Westheel V, Thomas M, Van Schill P, Vansteenkiste J, Manegold C, Miramanoff 
RO, Pignon J, Roccmans P, Shepherd FA. Induction treatment before surgery for non-small cell 
lung cancer: IASLC consensus report. Lung Cancer. 2003; 42:S9–14. [PubMed: 14708516] 
13. Pisters, K.; Mirkovik, N.; Pass, H.; Albain, KS. Lung Cancer: Principles and Practice. Third 
Edition. JB Lippincott Williams and Wilkins; 2005. Preoperative chemotherapy/radiation therapy 
for early stage and locally advanced non-small cell lung carcinoma.; p. 626-649.
14. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, 
McKenna RJ, Gandara DR, Miller TP, Taylor SA, Stelzer KJ, Beasley KR, Livingston RB. 
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) 
and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group phase II study 
8805. J Clin Oncol. 1995; 13:1880–92. [PubMed: 7636530] 
15. Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston 
RB. Concurrent cisplatin, etoposide and chest radiotherapy in pathologic stage IIIB non-small cell 
lung cancer: a Southwest Oncology Group Study (SWOG-9019). J Clin Oncology. 2002; 20:3454–
60.
16. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 1974; 
27:365–375. [PubMed: 4612056] 
17. Lakatos E. Sample size based on the long-rank statistic in complex clinical trials. Biometrics. 
1988; 44:229–241. [PubMed: 3358991] 
18. Cox D. Regression models and life-tables (with discussion). J Royal Statist Soc. 1972; 34:187–
220.Series B
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 
1958; 53:457–81.
20. Albain KS, Scott CB, Rusch VR, Turrisi AT, Shepherd FA, Smith C, Gandara DR, Johnson DH, 
Green MR, Miller RC, for RTOG, SWOG, NCIC-CTG, ECOG, CALGB; NCCTG. Phase III 
comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by 
Albain et al. Page 9













surgical resection for stage IIIA(pN2) non-small cell lung cancer: initial results from intergroup 
trial 0139 (RTOG 93-09). Proc Amer Soc Clin Oncol. 2003; 22:621.
21. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, 
Green MR, Miller RC. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs 
CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer: Outcomes 
update of North American Intergroup 0139 (RTOG-9309). J Clin Oncol. 2005; 23:624s.
22. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing preoperative chemotherapy 
and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer 
Inst. 1994; 86:673–630. [PubMed: 8158698] 
23. Rosell R, Gomez-Codina J, camps C, et al. A randomized trial comparing preoperative 
chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl 
J Med. 1994; 330:153–158. [PubMed: 8043059] 
24. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery 
compared with primary surgery in resectable stage I (except T1N0), II and IIIa non-small-cell lung 
cancer. J Clin Oncol. 2002; 20:247–253. [PubMed: 11773176] 
25. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection 
versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J 
Natl Cancer Inst. 2007; 99:442–50. [PubMed: 17374834] 
Albain et al. Page 10














Study R9309 (INT0139) design, consort diagram and treatment delivered. NSCLC, non-
small cell lung carcinoma
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Panel A. Progression-free survival (intent-to-treat). Panel B. Overall survival (intent-to-
treat). Slash marks represent censored observations. CT/RT/S, chemotherapy plus 
radiotherapy followed by surgery (arm 1); CT/RT, chemotherapy plus radiotherapy (arm 2)
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Overall survival within arm 1 by pathologic substage determined following thoracotomy.
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Panel A. Lobectomy subset from arm 1 vs matched cohort in arm 2, overall survival (intent-
to-treat). Panel B. Pneumonectomy subset from arm 1 vs matched cohort in arm 2, overall 
survival (intent-to-treat). Slash marks represent censored observations. CT/RT/S, 
chemotherapy plus radiotherapy followed by surgery (arm 1); CT/RT, chemotherapy plus 
radiotherapy (arm 2)
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Table 1
Pretreatment Characteristics of Eligible Patients
Arm 1 CT/RT/S (n=202) Arm 2 CT/RT (n=194) Total (n=396)
Age
    Median (years) 59 61 60
    Range (years) 31-77 32-78 31-78
    ≤ 60 113 (55.9%) 95 (49.0%) 208 (52.5%)
    > 60* 89 (44.1%) 99 (51.0%) 188 (47.5%)
Sex
    Male 131 (64.9%) 121 (62.4%) 252 (63.6%)
    Female 71 (35.1%) 73 (37.6%) 144 (36.4%)
Karnofsky Performance Status
    70-80 23 (11.4%) 25(12.9%) 48 (12.1%)
    90-100 179 (88.6%) 169 (87.1%) 348 (87.9%)
Estimated weight loss in previous 6 months
        <5 kg 154 (76.2%) 146 (75.3%) 299 (75.5%)
    5-10 kg 36 (17.8%) 30 (15.5%) 67 (16.9%)
    >10 kg 7 (3.5%) 10 (5.2%) 17 (4.3%)
    Unknown 5 (2.5%) 8 (4.1%) 13 (3.3%)
LDH
    Normal 148 (73.3%) 147 (75.8%) 295(74.5%)
    Abnormal 39 (19.3%) 33 (17.0%) 72 (18.2%)
    Not done 15 (7.4%) 14 (7.2%) 29 (7.3%)
Histology
    Squamous cell carcinoma 64 (31.7%) 65 (33.5%) 129 (32.6%)
    Adenocarcinoma 79 (39.1%) 82 (42.3%) 161 (40.7%)
    Large cell 29 (14.4%) 24 (12.4%) 53 (13.4%)
    Mixed/other NSCLC 30 (14.9%) 23 (11.9%) 53 (13.4%)
T-stage
    T1 50 (24.8%) 47 (24.2%) 97 (24.5%)
    T2 130 (64.4%) 121 (62.4%) 251 (63.4%)
    T3 22 (10.9%) 26 (13.4%) 48 (12.1%)
Number of positive nodal stations reported **
    1 153 (75.7%) 146 (75.3%) 299 (75.5%)
    2 39 (19.3%) 39 (20.1%) 78 (19.7%)
    3 4 (2.0%) 4 (2.1%) 8 (2.0%)
    Unknown 6 (3.0%) 5 (2.6%) 11 (2.8%)
*
63 (15.9%) of patients were ≥ 70 years
**
Not all patients had mediastinoscopy, since method of documentation of N2 disease was at the discretion of the investigator
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